$12 billion star anticoagulant market, Qingfeng Pharmaceutical will march into the market

Recently, Jiangxi Qingfeng Pharmaceutical'sapplication for Apixaban tablets (acceptance number CYHS1800008) submittedunder the generic category 4 was approved, and the approval number was H20203204. Apixaban is a new type of oral anticoagulant drug, with global salesof 12.149 billion U.S. dollars in 2019. Qingfeng Pharmaceutical is the fourthapproved generic company for this product.

New registration classification of Apixaban tablets：